LIFECORE BIOMEDICAL INC (LFCR) Fundamental Analysis & Valuation

NASDAQ:LFCR • US5147661046

Current stock price

5.34 USD
-0.04 (-0.74%)
Last:

This LFCR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. LFCR Profitability Analysis

1.1 Basic Checks

  • LFCR had negative earnings in the past year.
  • In the past year LFCR had a positive cash flow from operations.
  • LFCR had negative earnings in 4 of the past 5 years.
  • In the past 5 years LFCR reported 4 times negative operating cash flow.
LFCR Yearly Net Income VS EBIT VS OCF VS FCFLFCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • LFCR's Return On Assets of -18.71% is on the low side compared to the rest of the industry. LFCR is outperformed by 64.91% of its industry peers.
  • LFCR has a worse Return On Equity (-119.61%) than 82.46% of its industry peers.
Industry RankSector Rank
ROA -18.71%
ROE -119.61%
ROIC N/A
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
LFCR Yearly ROA, ROE, ROICLFCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

1.3 Margins

  • The Gross Margin of LFCR (30.57%) is worse than 71.93% of its industry peers.
  • In the last couple of years the Gross Margin of LFCR has grown nicely.
  • LFCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
LFCR Yearly Profit, Operating, Gross MarginsLFCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60 -80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. LFCR Health Analysis

2.1 Basic Checks

  • LFCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LFCR has more shares outstanding
  • The number of shares outstanding for LFCR has been increased compared to 5 years ago.
  • Compared to 1 year ago, LFCR has a worse debt to assets ratio.
LFCR Yearly Shares OutstandingLFCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
LFCR Yearly Total Debt VS Total AssetsLFCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • LFCR has an Altman-Z score of 0.32. This is a bad value and indicates that LFCR is not financially healthy and even has some risk of bankruptcy.
  • LFCR has a Altman-Z score of 0.32. This is in the lower half of the industry: LFCR underperforms 70.18% of its industry peers.
  • LFCR has a debt to FCF ratio of 6.62. This is a slightly negative value and a sign of low solvency as LFCR would need 6.62 years to pay back of all of its debts.
  • LFCR's Debt to FCF ratio of 6.62 is fine compared to the rest of the industry. LFCR outperforms 64.91% of its industry peers.
  • A Debt/Equity ratio of 3.67 is on the high side and indicates that LFCR has dependencies on debt financing.
  • The Debt to Equity ratio of LFCR (3.67) is worse than 91.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.67
Debt/FCF 6.62
Altman-Z 0.32
ROIC/WACCN/A
WACC9.1%
LFCR Yearly LT Debt VS Equity VS FCFLFCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 2.80 indicates that LFCR has no problem at all paying its short term obligations.
  • LFCR has a Current ratio of 2.80. This is comparable to the rest of the industry: LFCR outperforms 50.88% of its industry peers.
  • LFCR has a Quick Ratio of 1.67. This is a normal value and indicates that LFCR is financially healthy and should not expect problems in meeting its short term obligations.
  • LFCR has a Quick ratio (1.67) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 1.67
LFCR Yearly Current Assets VS Current LiabilitesLFCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. LFCR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.48% over the past year.
  • The Revenue has grown by 33.67% in the past year. This is a very strong growth!
  • Measured over the past years, LFCR shows a decrease in Revenue. The Revenue has been decreasing by -4.25% on average per year.
EPS 1Y (TTM)20.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.82%
Revenue 1Y (TTM)33.67%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%25.93%

3.2 Future

  • Based on estimates for the next years, LFCR will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.27% on average per year.
  • LFCR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.24% yearly.
EPS Next Y28.52%
EPS Next 2Y12.66%
EPS Next 3Y8.27%
EPS Next 5YN/A
Revenue Next Year-4.2%
Revenue Next 2Y0.31%
Revenue Next 3Y6.09%
Revenue Next 5Y21.24%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LFCR Yearly Revenue VS EstimatesLFCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
LFCR Yearly EPS VS EstimatesLFCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

2

4. LFCR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LFCR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LFCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LFCR Price Earnings VS Forward Price EarningsLFCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as LFCR.
  • Based on the Price/Free Cash Flow ratio, LFCR is valued cheaper than 96.49% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.75
EV/EBITDA 497.25
LFCR Per share dataLFCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.66%
EPS Next 3Y8.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LFCR Dividend Analysis

5.1 Amount

  • No dividends for LFCR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LFCR Fundamentals: All Metrics, Ratios and Statistics

LIFECORE BIOMEDICAL INC

NASDAQ:LFCR (4/16/2026, 9:55:09 AM)

5.34

-0.04 (-0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-08
Earnings (Next)08-05
Inst Owners76.22%
Inst Owner Change0%
Ins Owners1.86%
Ins Owner Change0.66%
Market Cap200.14M
Revenue(TTM)174.18M
Net Income(TTM)-44.00M
Analysts81.82
Price Target6.63 (24.16%)
Short Float %7.07%
Short Ratio7.6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.81%
Min EPS beat(2)-18.46%
Max EPS beat(2)38.08%
EPS beat(4)2
Avg EPS beat(4)-43.02%
Min EPS beat(4)-207.19%
Max EPS beat(4)38.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.06%
Min Revenue beat(2)1.03%
Max Revenue beat(2)15.09%
Revenue beat(4)4
Avg Revenue beat(4)6.79%
Min Revenue beat(4)1.03%
Max Revenue beat(4)15.09%
Revenue beat(8)7
Avg Revenue beat(8)3.78%
Revenue beat(12)9
Avg Revenue beat(12)2.54%
Revenue beat(16)10
Avg Revenue beat(16)-5.94%
PT rev (1m)-25.71%
PT rev (3m)-25.71%
EPS NQ rev (1m)-26.32%
EPS NQ rev (3m)-26.32%
EPS NY rev (1m)-12.3%
EPS NY rev (3m)-12.3%
Revenue NQ rev (1m)-12.76%
Revenue NQ rev (3m)-12.76%
Revenue NY rev (1m)-5.76%
Revenue NY rev (3m)-5.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.15
P/FCF 9.75
P/OCF 13.67
P/B 5.44
P/tB 10.7
EV/EBITDA 497.25
EPS(TTM)-1.07
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)0.55
FCFY10.26%
OCF(TTM)0.39
OCFY7.32%
SpS4.65
BVpS0.98
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -18.71%
ROE -119.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.57%
FCFM 11.79%
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
F-Score6
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 3.67
Debt/FCF 6.62
Debt/EBITDA 210.62
Cap/Depr 417.67%
Cap/Sales 3.38%
Interest Coverage N/A
Cash Conversion 2284.71%
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 1.67
Altman-Z 0.32
F-Score6
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)177.04%
Cap/Depr(5y)161.61%
Cap/Sales(3y)15.06%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.82%
EPS Next Y28.52%
EPS Next 2Y12.66%
EPS Next 3Y8.27%
EPS Next 5YN/A
Revenue 1Y (TTM)33.67%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%25.93%
Revenue Next Year-4.2%
Revenue Next 2Y0.31%
Revenue Next 3Y6.09%
Revenue Next 5Y21.24%
EBIT growth 1Y90.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year685.5%
EBIT Next 3Y117.84%
EBIT Next 5YN/A
FCF growth 1Y286.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1379.29%
OCF growth 3YN/A
OCF growth 5YN/A

LIFECORE BIOMEDICAL INC / LFCR Fundamental Analysis FAQ

What is the fundamental rating for LFCR stock?

ChartMill assigns a fundamental rating of 3 / 10 to LFCR.


Can you provide the valuation status for LIFECORE BIOMEDICAL INC?

ChartMill assigns a valuation rating of 2 / 10 to LIFECORE BIOMEDICAL INC (LFCR). This can be considered as Overvalued.


What is the profitability of LFCR stock?

LIFECORE BIOMEDICAL INC (LFCR) has a profitability rating of 1 / 10.


What is the expected EPS growth for LIFECORE BIOMEDICAL INC (LFCR) stock?

The Earnings per Share (EPS) of LIFECORE BIOMEDICAL INC (LFCR) is expected to grow by 28.52% in the next year.